A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)

M. K. Wallack, K. McNally, M. Michaelides, J. Bash, A. Bartolucci, H. Siegler, Charles M. Balch, H. Wanebo

Research output: Contribution to journalArticle

Abstract

Forty-eight patients with nonrecurrent high risk Stage I and II malignant melanoma were treated with Vaccinia Melanoma Oncolysates (VMO). Six different dose levels and two different treatment regimens were tested. Thirty-two out of 48 patients completed the 12 months of therapy. Side effects were mild to moderate. Twenty-eight out of 48 patients remain free from disease with a mean survival of 19 months, while 20/48 patients have recurred with a mean time to recurrence of 6 months.

Original languageEnglish (US)
Pages (from-to)148-151
Number of pages4
JournalAmerican Surgeon
Volume52
Issue number3
StatePublished - 1986
Externally publishedYes

Fingerprint

Vaccinia
Immunotherapy
Melanoma
Neoplasms
Recurrence
Survival
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Wallack, M. K., McNally, K., Michaelides, M., Bash, J., Bartolucci, A., Siegler, H., ... Wanebo, H. (1986). A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO). American Surgeon, 52(3), 148-151.

A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO). / Wallack, M. K.; McNally, K.; Michaelides, M.; Bash, J.; Bartolucci, A.; Siegler, H.; Balch, Charles M.; Wanebo, H.

In: American Surgeon, Vol. 52, No. 3, 1986, p. 148-151.

Research output: Contribution to journalArticle

Wallack, MK, McNally, K, Michaelides, M, Bash, J, Bartolucci, A, Siegler, H, Balch, CM & Wanebo, H 1986, 'A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)', American Surgeon, vol. 52, no. 3, pp. 148-151.
Wallack, M. K. ; McNally, K. ; Michaelides, M. ; Bash, J. ; Bartolucci, A. ; Siegler, H. ; Balch, Charles M. ; Wanebo, H. / A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO). In: American Surgeon. 1986 ; Vol. 52, No. 3. pp. 148-151.
@article{0ab30fbc13764b308094004fe57b9142,
title = "A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)",
abstract = "Forty-eight patients with nonrecurrent high risk Stage I and II malignant melanoma were treated with Vaccinia Melanoma Oncolysates (VMO). Six different dose levels and two different treatment regimens were tested. Thirty-two out of 48 patients completed the 12 months of therapy. Side effects were mild to moderate. Twenty-eight out of 48 patients remain free from disease with a mean survival of 19 months, while 20/48 patients have recurred with a mean time to recurrence of 6 months.",
author = "Wallack, {M. K.} and K. McNally and M. Michaelides and J. Bash and A. Bartolucci and H. Siegler and Balch, {Charles M.} and H. Wanebo",
year = "1986",
language = "English (US)",
volume = "52",
pages = "148--151",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "3",

}

TY - JOUR

T1 - A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)

AU - Wallack, M. K.

AU - McNally, K.

AU - Michaelides, M.

AU - Bash, J.

AU - Bartolucci, A.

AU - Siegler, H.

AU - Balch, Charles M.

AU - Wanebo, H.

PY - 1986

Y1 - 1986

N2 - Forty-eight patients with nonrecurrent high risk Stage I and II malignant melanoma were treated with Vaccinia Melanoma Oncolysates (VMO). Six different dose levels and two different treatment regimens were tested. Thirty-two out of 48 patients completed the 12 months of therapy. Side effects were mild to moderate. Twenty-eight out of 48 patients remain free from disease with a mean survival of 19 months, while 20/48 patients have recurred with a mean time to recurrence of 6 months.

AB - Forty-eight patients with nonrecurrent high risk Stage I and II malignant melanoma were treated with Vaccinia Melanoma Oncolysates (VMO). Six different dose levels and two different treatment regimens were tested. Thirty-two out of 48 patients completed the 12 months of therapy. Side effects were mild to moderate. Twenty-eight out of 48 patients remain free from disease with a mean survival of 19 months, while 20/48 patients have recurred with a mean time to recurrence of 6 months.

UR - http://www.scopus.com/inward/record.url?scp=0022597646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022597646&partnerID=8YFLogxK

M3 - Article

C2 - 3513682

AN - SCOPUS:0022597646

VL - 52

SP - 148

EP - 151

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 3

ER -